BACKGROUND: The positive impact of opioid substitution treatment (OST) on opioid-dependent individuals with human immunodeficiency virus (HIV) infection is well documented, especially with regard to adherence to highly active antiretroviral therapy (HAART). We used the data from a 5-year longitudinal study of the MANIF 2000 cohort of individuals infected with HIV (as a result of injection drug use) and receiving HAART to investigate the predictors of long-term virological success. Design. Data were collected every 6 months from outpatient hospital services delivering HIV care in France. We selected all patients who were receiving HAART for at least 6 months (baseline visit) and who had indications for OST (ie, still dependent on opioids). We selected a total of 113 patients, accounting for a total of 562 visits for all the analyses. METHODS: Long-term virological success was defined as an undetectable viral load after at least 6 months on HAART. Retention in OST was defined as the time interval between the last initiation or reinitiation of OST during HAART follow-up and any given visit on OST. A mixed logistic model was used to identify predictors of long-term virological success. RESULTS: At baseline, 53 patients were receiving buprenorphine, 28 patients were receiving methadone, and 32 patients were not on OST. The median duration of OST was 25 months (range, 3-42 months). In the multivariate analysis, after adjustment for significant predictors of long-term virological success such as adherence to HAART and early virological response, retention in OST was associated with long-term virological success (odds ratio, 1.20 per 6-month increase; 95% confidence interval, 1.09-1.32). CONCLUSIONS: Our study presents important evidence of the positive impact of retention in OST on HIV outcomes. Increasing access to OST based on a comprehensive model of care for HIV-infected patients who have indications for OST may foster adherence and ensure long-term response to HAART.
BACKGROUND: The positive impact of opioid substitution treatment (OST) on opioid-dependent individuals with human immunodeficiency virus (HIV) infection is well documented, especially with regard to adherence to highly active antiretroviral therapy (HAART). We used the data from a 5-year longitudinal study of the MANIF 2000 cohort of individuals infected with HIV (as a result of injection drug use) and receiving HAART to investigate the predictors of long-term virological success. Design. Data were collected every 6 months from outpatient hospital services delivering HIV care in France. We selected all patients who were receiving HAART for at least 6 months (baseline visit) and who had indications for OST (ie, still dependent on opioids). We selected a total of 113 patients, accounting for a total of 562 visits for all the analyses. METHODS: Long-term virological success was defined as an undetectable viral load after at least 6 months on HAART. Retention in OST was defined as the time interval between the last initiation or reinitiation of OST during HAART follow-up and any given visit on OST. A mixed logistic model was used to identify predictors of long-term virological success. RESULTS: At baseline, 53 patients were receiving buprenorphine, 28 patients were receiving methadone, and 32 patients were not on OST. The median duration of OST was 25 months (range, 3-42 months). In the multivariate analysis, after adjustment for significant predictors of long-term virological success such as adherence to HAART and early virological response, retention in OST was associated with long-term virological success (odds ratio, 1.20 per 6-month increase; 95% confidence interval, 1.09-1.32). CONCLUSIONS: Our study presents important evidence of the positive impact of retention in OST on HIV outcomes. Increasing access to OST based on a comprehensive model of care for HIV-infectedpatients who have indications for OST may foster adherence and ensure long-term response to HAART.
Authors: Ryan McNeil; Thomas Kerr; Solanna Anderson; Lisa Maher; Chereece Keewatin; M J Milloy; Evan Wood; Will Small Journal: Soc Sci Med Date: 2015-04-07 Impact factor: 4.634
Authors: Nadine E Chen; Jaimie P Meyer; Ann K Avery; Jeffrey Draine; Timothy P Flanigan; Thomas Lincoln; Anne C Spaulding; Sandra A Springer; Frederick L Altice Journal: AIDS Behav Date: 2013-10
Authors: Chethan Bachireddy; Michael C Soule; Jacob M Izenberg; Sergey Dvoryak; Konstantin Dumchev; Frederick L Altice Journal: Drug Alcohol Depend Date: 2013-09-27 Impact factor: 4.492
Authors: David S Metzger; Deborah Donnell; David D Celentano; J Brooks Jackson; Yiming Shao; Apinun Aramrattana; Liu Wei; Liping Fu; Jun Ma; Gregory M Lucas; Marek Chawarski; Yuhua Ruan; Paul Richardson; Katherine Shin; Ray Y Chen; Jeremy Sugarman; Bonnie J Dye; Scott M Rose; Geetha Beauchamp; David N Burns Journal: J Acquir Immune Defic Syndr Date: 2015-04-15 Impact factor: 3.731
Authors: Evgeny Krupitsky; Elena Blokhina; Edwin Zvartau; Elena Verbitskaya; Dmitri Lioznov; Tatiana Yaroslavtseva; Vladimir Palatkin; Marina Vetrova; Natalia Bushara; Andrei Burakov; Dmitri Masalov; Olga Mamontova; Daniel Langleben; Sabrina Poole; Robert Gross; George Woody Journal: Lancet HIV Date: 2019-03-14 Impact factor: 12.767
Authors: Bryan Hartzler; Julia C Dombrowski; Heidi M Crane; Joseph J Eron; Elvin H Geng; W Christopher Mathews; Kenneth H Mayer; Richard D Moore; Michael J Mugavero; Sonia Napravnik; Benigno Rodriguez; Dennis M Donovan Journal: AIDS Behav Date: 2017-04
Authors: Bohdan Nosyk; Jeong E Min; Guillaume Colley; Viviane D Lima; Benita Yip; M-J S Milloy; Evan Wood; Julio S G Montaner Journal: AIDS Date: 2015-05-15 Impact factor: 4.177
Authors: Kathleen A McGinnis; David A Fiellin; Melissa Skanderson; Yih-Ing Hser; Gregory M Lucas; Amy C Justice; Janet P Tate Journal: Drug Alcohol Depend Date: 2019-09-04 Impact factor: 4.492